Look back at pharma news to Nov 4

It is starting to get ugly in the markets with the Nasdaq and S&P 500 posting their eight straight losing trading session Thursday. The US Department of Justice - which has some interesting choices of what it is and what it is not targeting this election year - deals the latest blow to the biopharma sector, wrote Bret Jensen on the Seeking Alpha blog.

The "leaked" DoJ investigatory news around criminal charges for collusion and price fixing in the generics industry were well timed to hit just days before the election. There was also a call to the DoJ, as well as the Federal Trade Commission, to investigate collusion on pricing by makers of  insulin products.

If the election isn't enough to bring biotech investors down, the DoJ - which has some interesting choices of what they choose to target these days - piled on this beaten down sector. Biotech lost 3% on the day as Bloomberg reported the Feds could file charges before the end of the year in their probe over whether companies colluded on drug pricing.